Geron (GERN) AI Stock Analysis

• Market Cap: $803.90M
• Dividend Yield: N/A
• Average Volume (3M): 7.38M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.36
• Revenue Growth: 11877.28%
• EPS Growth: 63.14%
• Country: US
• Employees: 229
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 638,017,100
• 10 Day Avg. Volume: 5,950,470
• 30 Day Avg. Volume: 7,379,608
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.99
• Enterprise Value/Revenue: 4.86
• Enterprise Value/Gross Profit: 4.96
• Enterprise Value/Ebitda: -12.53
• 1Y Price Target: $3.50
• Price Target Upside: 177.78% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 6

• Rating: 50 Neutral
• Price Target: $1.50 ▲(19.05% Upside)

Geron's overall stock score reflects strong revenue growth and strategic initiatives for RYTELO, but is tempered by ongoing profitability challenges, bearish technical indicators, and valuation concerns. The earnings call provided positive insights into future growth, yet highlighted some operational challenges.

Positive Factors

Revenue Growth

The significant revenue growth for RYTELO indicates strong market demand and successful commercialization efforts, supporting long-term business expansion.

Market Expansion

Expanding the sales force and medical affairs team enhances market penetration and customer engagement, crucial for sustaining growth and competitive advantage.

Strong Payer Access

High payer access ensures broad patient reach and revenue stability, crucial for long-term success in the competitive pharmaceutical market.

Negative Factors

Profitability Challenges

Ongoing losses and negative profit margins highlight the need for improved cost management and operational efficiency to achieve sustainable profitability.

Cash Flow Issues

Negative cash flows indicate operational cash burn, which can limit the company's ability to invest in growth and innovation without additional financing.

European Commercialization Uncertainty

Uncertainty in European market entry poses a risk to international expansion plans, potentially affecting future revenue streams and market diversification.

Geron Business Overview & Revenue Model

Company Description

Geron Corporation (GERN) is a biopharmaceutical company focused on the development of innovative therapies for cancer treatment. The company specializes in telomere biology and is primarily engaged in the research and development of drugs that target telomerase, an enzyme that plays a crucial role in cancer cell immortality. Geron's lead product candidate, imetelstat, is an investigational telomerase inhibitor being studied for its potential to treat hematologic malignancies, particularly myelofibrosis and acute myeloid leukemia.

How the Company Makes Money

Geron generates revenue primarily through collaborations, partnerships, and potential future product sales. The company has engaged in strategic collaborations with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on product sales. As Geron advances its clinical trials and potentially gains regulatory approval for its drug candidates, it may also start to generate revenue from product sales. Additionally, the company may receive funding through grants and research contracts, especially if its therapies demonstrate significant promise in clinical trials.

Geron Financial Statement Overview

Summary

Geron's financials show significant challenges with profitability, marked by negative net income and EBIT margins. Despite revenue growth, the company faces persistent net losses and negative cash flows, indicating financial strain and sustainability concerns.

Income Statement

Geron's income statement reveals significant challenges with profitability, as highlighted by negative net income and EBIT margins over the periods analyzed. Despite a sharp increase in total revenue in the TTM period, the company still reports significant net losses, affecting its overall profitability. This indicates ongoing financial strain likely due to high operational costs or expenses exceeding revenue gains.

Balance Sheet

The balance sheet indicates moderate financial health with a relatively stable debt-to-equity ratio. The company's equity ratio shows a reasonable proportion of equity financing, though total liabilities have been increasing, reflecting potential leverage concerns. However, the consistent increase in total assets suggests investment and growth potential.

Cash Flow

Geron's cash flow statements highlight negative free cash flow and operating cash flows, indicating cash burn likely due to ongoing investments or operational challenges. Although there are positive financing cash flows, the inability to generate positive operating cash flow is concerning for long-term sustainability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	164.45M	76.99M	237.00K	596.00K	1.39M	253.00K
Gross Profit	161.21M	75.74M	-123.50M	-272.00K	610.00K	-49.80M
EBITDA	-63.78M	-154.85M	-174.78M	-134.15M	-111.59M	-73.92M
Net Income	-88.01M	-174.57M	-184.13M	-141.03M	-120.95M	-75.61M
Balance Sheet
Total Assets	555.20M	594.46M	394.08M	190.57M	226.03M	270.73M
Cash, Cash Equivalents and Short-Term Investments	387.98M	406.57M	333.70M	173.11M	183.72M	196.64M
Total Debt	121.84M	121.72M	85.90M	55.75M	55.00M	29.72M
Total Liabilities	295.67M	313.46M	146.13M	110.58M	99.62M	59.78M
Stockholders Equity	259.53M	280.32M	247.95M	80.00M	126.42M	210.95M
Cash Flow
Free Cash Flow	-178.28M	-219.30M	-168.57M	-127.81M	-95.76M	-67.05M
Operating Cash Flow	-178.28M	-218.62M	-167.74M	-127.38M	-95.56M	-66.65M
Investing Cash Flow	-31.31M	-106.00M	-180.32M	62.07M	71.95M	-105.32M
Financing Cash Flow	171.09M	334.37M	362.02M	87.26M	48.56M	168.35M

Geron Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GERN, the sentiment is Negative. The current price of 1.26 is below the 20-day moving average (MA) of 1.27, below the 50-day MA of 1.32, and below the 200-day MA of 1.60, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 47.60 is Neutral, neither overbought nor oversold. The STOCH value of 37.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GERN.

Geron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ANAB	―	$1.02B	-8.17	―	―	304.17%	29.37%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GERN	―	$803.90M	-9.51	-31.09%	―	11877.28%	63.14%
SNDX	―	$1.18B	―	-113.22%	―	2133.71%	-15.38%
QURE	―	$4.17B	―	-427.47%	―	-48.25%	33.77%
CRMD	―	$872.02M	14.91	38.35%	―	14970.29%	―
AVBP	―	$791.50M	―	-50.13%	―	―	-79.41%

Geron Corporate Events

Geron Announces Executive Leadership Transitions

On October 10, 2025, Geron Corporation announced the resignation of board member Dr. Gaurav Aggarwal and the decision of Dr. V. Bryan Lawlis not to stand for re-election at the 2026 Annual Meeting. Additionally, on October 15, 2025, executives Andrew J. Grethlein and Jim Ziegler departed from their roles, with Grethlein transitioning to a consulting role to assist with the transition. On October 13, 2025, Geron announced several executive leadership transitions, appointing Ahmed ElNawawi as the new Executive Vice President, Chief Commercial Officer, along with three other seasoned executives to strengthen its leadership team. These changes aim to align the company’s leadership structure with its strategic priorities, focusing on driving growth and maximizing the potential of RYTELO®.

The most recent analyst rating on (GERN) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Geron stock, see the GERN Stock Forecast page.

Geron Corporation’s Phase 3 Study on Imetelstat: A Potential Game-Changer for Myelofibrosis Treatment

Geron Corporation is conducting a Phase 3 clinical study titled ‘A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor.’ The study aims to assess the overall survival of participants with intermediate-2 or high-risk Myelofibrosis who have not responded to JAK-Inhibitor treatment, highlighting its significance in addressing unmet medical needs in this patient population.

Geron Corporation’s Phase 3 Study on Imetelstat: A Potential Game-Changer for Myelofibrosis Treatment

Geron Corporation is conducting a Phase 3 clinical study titled A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor. The study aims to assess the overall survival of participants receiving imetelstat compared to those receiving the best available therapy, targeting patients with intermediate-2 or high-risk MF who have not responded to JAK-inhibitor treatment.

Geron Corporation’s Phase 3 Study: A Potential Game-Changer for Myelofibrosis Treatment

Study Overview: Geron Corporation is conducting a Phase 3 clinical study titled A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat (GRN163L) Versus Best Available Therapy (BAT) in Patients With Intermediate-2 or High-risk Myelofibrosis (MF) Relapsed / Refractory (R/R) to Janus Kinase (JAK) Inhibitor. The study aims to assess the overall survival of participants treated with imetelstat compared to BAT in patients who have not responded to JAK-inhibitor treatment, highlighting its potential significance in advancing treatment options for this patient group.

Geron Corporation Reports Strong Q2 2025 Results

Geron Corporation is a commercial-stage biopharmaceutical company focused on developing innovative treatments for blood cancers, with a unique emphasis on telomerase inhibition. The company has recently reported its second-quarter financial results for 2025, highlighting significant progress in its commercial and clinical endeavors.

Geron Corporation’s Earnings Call Highlights Growth and Challenges

Geron Corporation’s recent earnings call conveyed a positive sentiment, driven by significant revenue growth and strategic expansions in both commercial and medical teams. The company has successfully increased physician awareness and secured favorable payer coverage, although challenges remain in early line usage and data limitations on patient retention.

Geron Appoints Harout Semerjian as New CEO

On August 1, 2025, Geron Corporation’s Board of Directors appointed Harout Semerjian as the new President and CEO, effective August 7, 2025, replacing Dawn C. Bir. Mr. Semerjian brings extensive experience from his previous roles in the biotechnology and pharmaceutical sectors, including leadership positions at GlycoMimetics, Immunomedics, and Ipsen Pharma. The appointment is accompanied by an employment agreement that includes a substantial compensation package and stock options, reflecting the company’s strategic focus on strengthening its leadership team. Additionally, the company amended its severance plan and inducement award plan to align with these leadership changes, indicating a commitment to attracting and retaining top talent in the industry.

The most recent analyst rating on (GERN) stock is a Buy with a $9.00 price target. To see the full list of analyst forecasts on Geron stock, see the GERN Stock Forecast page.